Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIA 6-512 PK Interaction with Levodopa
NCT03094156Phase 1Completed
- Sponsor
- BIAL
- Start
- Apr 2006
- Primary completion
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of resveratrol in Parkinson's disease (PD) (5 arms), sponsored by BIAL. Primary endpoints: Maximum observed plasma drug concentration at Day 5, Time of occurrence of Cmax at Day 5 and 4 more. Started Apr 2006; status: completed.
02
Drugs
resveratrol
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03094156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03094156.